Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer-Reference-Cited by-同舟云学术

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer

Published:2019-02-18 Issue:2 Volume:2019 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Zaheed Milita¹,Wilcken Nicholas²³,Willson Melina L⁴,O'Connell Dianne L⁵,Goodwin Annabel¹⁶⁷

Affiliation:

1. Concord Repatriation General Hospital; Medical Oncology Department; Concord New South Wales Australia 2139

2. Crown Princess Mary Cancer Centre; Medical Oncology; Westmead NSW Australia 2145

3. The University of Sydney; Sydney Medical School; Sydney Australia

4. NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450

5. Cancer Council NSW; Cancer Research Division; PO Box 572 Kings Cross Sydney NSW Australia 1340

6. The University of Sydney, Concord Repatriation General Hospital; Concord Clinical School; Concord NSW Australia 2137

7. Sydney Local Health District and South Western Sydney Local Health District; Cancer Genetics Department; Sydney Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012873.pub2/epdf/full

Reference61 articles.

1. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer;Abe;International Journal of Clinical Oncology,2013

2. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer;Buzdar;Lancet,2013

3. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer;Buzdar;Journal of Clinical Oncology,2013

4. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study;Piedbois;Annals of Oncology,2007

5. ACTRN12605000588695 Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response anzctr.org.au/trial/registration/ANTRN12605000588695

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological complete response of locally advanced triple-negative breast cancer: case report;Siberian journal of oncology;2024-09-10

2. Differences in severity of chemotherapy-induced nausea and vomiting between neoadjuvant and adjuvant chemotherapy in patients with breast cancer: analysis of data from two prospective observational studies;Supportive Care in Cancer;2024-07-13

3. Adjuvant and Neoadjuvant Therapy for Breast Cancer: A Systematic Review;European Journal of Breast Health;2024-07-01

4. Synergistic effects and competitive relationships between DOC and DOX as acting on DNA molecules: Studied with confocal Raman spectroscopy and molecular docking technology;Heliyon;2024-05

5. Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients;Xenobiotica;2024-03-15